Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients

Peter B. Gwilt, Konstantine K. Manouilov, JoCarol McNabb, Susan Swindells

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Hydroxyurea has been shown to potentiate the activity of the antiretroviral nucleoside analogs. A significant complication of AIDS is invasion of the virus into the CNS, resulting in HIV-associated dementia (HAD). Because of the polar nature of these nucleosides and the presence of efflux pumps in the blood-brain barrier, only low CNS drug concentrations are achieved. Introduction of hydroxyurea into the CNS may therefore increase the antiviral activity of these drugs. This study evaluates the accessibility of hydroxyurea to the CNS following oral drug administration. Twelve HIV patients received 800 mg, 1000 mg, or 1200 mg oral hydroxyurea. Cerebrospinal fluid (CSF) and plasma drug concentrations were measured over 8 hours and simultaneously fitted to a pharmacokinetic model. It was determined that CSF hydroxyurea concentrations, corresponding to those found to increase antiretroviral nucleoside activity in vitro, were achieved.

Original languageEnglish (US)
Pages (from-to)1003-1007
Number of pages5
JournalJournal of Clinical Pharmacology
Volume43
Issue number9
DOIs
StatePublished - Sep 1 2003

Fingerprint

Hydroxyurea
Cerebrospinal Fluid
HIV-1
Pharmacokinetics
Nucleosides
AIDS Dementia Complex
Blood-Brain Barrier
Pharmaceutical Preparations
Antiviral Agents
Oral Administration
Acquired Immunodeficiency Syndrome
HIV
Viruses

Keywords

  • Antiretroviral drugs
  • HIV-associated dementia
  • Hydroxyurea
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients. / Gwilt, Peter B.; Manouilov, Konstantine K.; McNabb, JoCarol; Swindells, Susan.

In: Journal of Clinical Pharmacology, Vol. 43, No. 9, 01.09.2003, p. 1003-1007.

Research output: Contribution to journalArticle

Gwilt, Peter B. ; Manouilov, Konstantine K. ; McNabb, JoCarol ; Swindells, Susan. / Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients. In: Journal of Clinical Pharmacology. 2003 ; Vol. 43, No. 9. pp. 1003-1007.
@article{c4c98d60275542b486f1801c70381f69,
title = "Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients",
abstract = "Hydroxyurea has been shown to potentiate the activity of the antiretroviral nucleoside analogs. A significant complication of AIDS is invasion of the virus into the CNS, resulting in HIV-associated dementia (HAD). Because of the polar nature of these nucleosides and the presence of efflux pumps in the blood-brain barrier, only low CNS drug concentrations are achieved. Introduction of hydroxyurea into the CNS may therefore increase the antiviral activity of these drugs. This study evaluates the accessibility of hydroxyurea to the CNS following oral drug administration. Twelve HIV patients received 800 mg, 1000 mg, or 1200 mg oral hydroxyurea. Cerebrospinal fluid (CSF) and plasma drug concentrations were measured over 8 hours and simultaneously fitted to a pharmacokinetic model. It was determined that CSF hydroxyurea concentrations, corresponding to those found to increase antiretroviral nucleoside activity in vitro, were achieved.",
keywords = "Antiretroviral drugs, HIV-associated dementia, Hydroxyurea, Pharmacokinetics",
author = "Gwilt, {Peter B.} and Manouilov, {Konstantine K.} and JoCarol McNabb and Susan Swindells",
year = "2003",
month = "9",
day = "1",
doi = "10.1177/0091270003256144",
language = "English (US)",
volume = "43",
pages = "1003--1007",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients

AU - Gwilt, Peter B.

AU - Manouilov, Konstantine K.

AU - McNabb, JoCarol

AU - Swindells, Susan

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Hydroxyurea has been shown to potentiate the activity of the antiretroviral nucleoside analogs. A significant complication of AIDS is invasion of the virus into the CNS, resulting in HIV-associated dementia (HAD). Because of the polar nature of these nucleosides and the presence of efflux pumps in the blood-brain barrier, only low CNS drug concentrations are achieved. Introduction of hydroxyurea into the CNS may therefore increase the antiviral activity of these drugs. This study evaluates the accessibility of hydroxyurea to the CNS following oral drug administration. Twelve HIV patients received 800 mg, 1000 mg, or 1200 mg oral hydroxyurea. Cerebrospinal fluid (CSF) and plasma drug concentrations were measured over 8 hours and simultaneously fitted to a pharmacokinetic model. It was determined that CSF hydroxyurea concentrations, corresponding to those found to increase antiretroviral nucleoside activity in vitro, were achieved.

AB - Hydroxyurea has been shown to potentiate the activity of the antiretroviral nucleoside analogs. A significant complication of AIDS is invasion of the virus into the CNS, resulting in HIV-associated dementia (HAD). Because of the polar nature of these nucleosides and the presence of efflux pumps in the blood-brain barrier, only low CNS drug concentrations are achieved. Introduction of hydroxyurea into the CNS may therefore increase the antiviral activity of these drugs. This study evaluates the accessibility of hydroxyurea to the CNS following oral drug administration. Twelve HIV patients received 800 mg, 1000 mg, or 1200 mg oral hydroxyurea. Cerebrospinal fluid (CSF) and plasma drug concentrations were measured over 8 hours and simultaneously fitted to a pharmacokinetic model. It was determined that CSF hydroxyurea concentrations, corresponding to those found to increase antiretroviral nucleoside activity in vitro, were achieved.

KW - Antiretroviral drugs

KW - HIV-associated dementia

KW - Hydroxyurea

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0041511683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041511683&partnerID=8YFLogxK

U2 - 10.1177/0091270003256144

DO - 10.1177/0091270003256144

M3 - Article

VL - 43

SP - 1003

EP - 1007

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 9

ER -